HC Wainwright Reaffirms “Buy” Rating for Atyr PHARMA (NASDAQ:ATYR)

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note published on Monday morning, Benzinga reports. They currently have a $35.00 price objective on the stock.

Atyr PHARMA Trading Up 3.2 %

ATYR stock opened at $1.93 on Monday. The firm has a market capitalization of $133.19 million, a price-to-earnings ratio of -2.14 and a beta of 1.25. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 1 year low of $1.08 and a 1 year high of $2.15.

Insider Activity at Atyr PHARMA

In other Atyr PHARMA news, Director Paul Schimmel purchased 52,300 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was bought at an average price of $1.93 per share, with a total value of $100,939.00. Following the completion of the purchase, the director now owns 413,023 shares in the company, valued at approximately $797,134.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.70% of the stock is owned by insiders.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.